Susanne M Benseler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/361918/publications.pdf

Version: 2024-02-01

164 papers 13,546 citations

50 h-index

23472 111 g-index

171 all docs

171 docs citations

times ranked

171

11668 citing authors

#	Article	IF	Citations
1	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Rheumatology, 2023, 62, SI170-SI180.	0.9	4
2	Costs of <scp>Hospitalâ€Associated</scp> Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. Arthritis Care and Research, 2022, 74, 1585-1592.	1.5	3
3	Secondary consequences of juvenile idiopathic arthritis in children and adolescents with knee involvement: physical activity, adiposity, fitness, and functional performance. Rheumatology International, 2022, 42, 319-327.	1.5	8
4	Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study. Clinical and Experimental Rheumatology, 2022, , .	0.4	1
5	Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient, 2022, 15, 599-609.	1.1	3
6	A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis and Rheumatology, 2022, 74, 1409-1419.	2.9	7
7	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatric Rheumatology, 2022, 20, 25.	0.9	8
8	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukinâ€1 Mediated Autoinflammatory Diseases: Cryopyrinâ€Associated Periodic Syndromes, Tumour Necrosis Factor Receptorâ€Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukinâ€1 Receptor Antagonist. Arthritis and Rheumatology, 2022,	2.9	14
9	The 2022 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases,	0.5	38
10	Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 975-984.	0.7	8
11	A Populationâ€Based Approach to Reporting System–Level Performance Measures for Rheumatoid Arthritis Care. Arthritis Care and Research, 2021, 73, 640-648.	1.5	12
12	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 760-766.	1.0	0
13	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. Journal of Rheumatology, 2021, 48, 555-566.	1.0	27
14	Different Disease Endotypes in Phenotypically Similar Vasculitides Affecting Small-to-Medium Sized Blood Vessels. Frontiers in Immunology, 2021, 12, 638571.	2.2	7
15	Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood. Frontiers in Immunology, 2021, 12, 516427.	2.2	7
16	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 97.	0.9	8
17	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	70
18	Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatology and Therapy, 2021, 8, 1303-1322.	1.1	6

#	Article	IF	CITATIONS
19	Higher concentrations of vitamin D in Canadian children with juvenile idiopathic arthritis compared to healthy controls are associated with more frequent use of vitamin D supplements and season of birth. Nutrition Research, 2021, 92, 139-149.	1.3	5
20	Colchicine $\hat{a}\in$ " an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants. Pediatric Rheumatology, 2021, 19, 142.	0.9	5
21	Use and Safety of Immunotherapeutic Management of <i>N</i> -Methyl- <scp>d</scp> -Aspartate Receptor Antibody Encephalitis. JAMA Neurology, 2021, 78, 1333.	4.5	91
22	Evaluating Quality of Care for Rheumatoid Arthritis for the Population of Alberta Using System-level Performance Measures. Journal of Rheumatology, 2021, 48, 482-485.	1.0	9
23	Colchicine Effectiveness and Safety in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis. Frontiers in Pediatrics, 2021, 9, 759664.	0.9	13
24	Genomic Health Literacy Interventions in Pediatrics: Scoping Review. Journal of Medical Internet Research, 2021, 23, e26684.	2.1	4
25	Gait Adaptations in Youth With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 72, 917-924.	1.5	14
26	Realâ€World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. Arthritis Care and Research, 2020, 72, 897-906.	1.5	14
27	Association of neonatal inflammatory markers and perinatal stroke subtypes. Neurology, 2020, 95, e1163-e1173.	1.5	8
28	New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. Rheumatology, 2020, 59, 3259-3263.	0.9	23
29	Consequences of Juvenile Idiopathic Arthritis on Single Leg Squat Performance in Youth. Arthritis Care and Research, 2020, 73, 1187-1193.	1.5	4
30	Considering immunologic and genetic evaluation for HLH in neuroinflammation: A case of Griscelli syndrome type 2 with neurological symptoms and a lack of albinism. Pediatric Blood and Cancer, 2020, 67, e28312.	0.8	7
31	Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis. Pediatric Rheumatology, 2020, 18, 22.	0.9	9
32	A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Arthritis Research and Therapy, 2020, 22, 53.	1.6	8
33	Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatric Rheumatology, 2020, 18, 17.	0.9	41
34	Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	178
35	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 2402-2411.	0.9	11
36	Vertical Drop Jump Performance in Youth with Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 955-963.	1.5	10

#	Article	IF	Citations
37	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	3.9	142
38	Increased Arterial Stiffness Adversely Affects Left Ventricular Mechanics in Patients With Pediatric Takayasu Arteritis From a Toronto Cohort. Journal of Clinical Rheumatology, 2019, 25, 171-175.	0.5	8
39	Presentation and Disease Course of Childhoodâ€Onset Versus Adultâ€Onset Takayasu Arteritis. Arthritis and Rheumatology, 2019, 71, 315-323.	2.9	38
40	Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. BMC Health Services Research, 2019, 19, 572.	0.9	7
41	Strategies for treatment of childhood primary angiitis of the central nervous system. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e567.	3.1	28
42	Patientâ€Reported Barriers at School for Children with Juvenile Idiopathic Arthritis. ACR Open Rheumatology, 2019, 1, 182-187.	0.9	11
43	Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatric Rheumatology, 2019, 17, 20.	0.9	10
44	Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis and Rheumatology, 2019, 71, 1747-1755.	2.9	41
45	Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort. Journal of Rheumatology, 2019, 46, 628-635.	1.0	24
46	Reply. Arthritis and Rheumatology, 2019, 71, 836-838.	2.9	0
47	Cryopyrin-Associated Periodic Syndromes (CAPS). , 2019, , 95-109.		0
48	Cognitive outcomes of childhood primary CNS vasculitis Neuropsychology, 2019, 33, 462-469.	1.0	2
49	Rheum4U: Development and testing of a web-based tool for improving the quality of care for patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 385-392.	0.4	8
50	Cluster and Multiple Correspondence Analyses in Rheumatology. Rheumatic Disease Clinics of North America, 2018, 44, 349-360.e29.	0.8	8
51	Healthâ€Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care and Research, 2018, 70, 134-144.	1.5	50
52	Exercise Therapy in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Archives of Physical Medicine and Rehabilitation, 2018, 99, 178-193.e1.	0.5	71
53	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.5	9
54	The Utility of Collaterals as a Biomarker in Pediatric Unilateral Intracranial Arteriopathy. Pediatric Neurology, 2018, 78, 27-34.	1.0	8

#	Article	IF	Citations
55	S100A12 Serum Levels and PMN Counts Are Elevated in Childhood Systemic Vasculitides Especially Involving Proteinase 3 Specific Anti-neutrophil Cytoplasmic Antibodies. Frontiers in Pediatrics, 2018, 6, 341.	0.9	16
56	Health-related quality of life in children with inflammatory brain disease. Pediatric Rheumatology, 2018, 16, 73.	0.9	12
57	Living with autoinflammatory diseases: identifying unmet needs of children, adolescents and adults. Pediatric Rheumatology, 2018, 16, 81.	0.9	14
58	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
59	Feasibility of Measurement and Adherence to System Performance Measures for Rheumatoid Arthritis in 5 Models of Care. Journal of Rheumatology, 2018, 45, 1501-1508.	1.0	15
60	Neuroimmune disorders of the central nervous system in children in the molecular era. Nature Reviews Neurology, 2018, 14, 433-445.	4.9	41
61	Symptomatic adrenal suppression among children in Canada. Archives of Disease in Childhood, 2017, 102, 338.1-339.	1.0	29
62	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
63	Response to: †Criteria for CAPS, is it all in the name?' by Touitou and Sarrabay. Annals of the Rheumatic Diseases, 2017, 76, e10-e10.	0.5	O
64	Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1470-1479.	2.9	56
65	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.5	175
66	Predicting Which Children with Juvenile Idiopathic Arthritis Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort. Journal of Rheumatology, 2017, 44, 230-240.	1.0	41
67	Response to: †Why CAPS criteria are not diagnostic criteria?' by Landewé and van der Heijde. Annals of the Rheumatic Diseases, 2017, 76, e8-e8.	0.5	O
68	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
69	Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Research and Therapy, 2017, 19, 255.	1.6	54
70	Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 91-99.	0.8	6
71	Childhood Central Nervous System Vasculitis. , 2017, , 509-524.		O
72	Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis and Rheumatology, 2016, 68, 2514-2526.	2.9	103

#	Article	IF	CITATIONS
73	Arterial dissection in childhood Takayasu Arteritis: not as rare as thought. Pediatric Rheumatology, 2016, 14, 56.	0.9	13
74	Central nervous system vasculitis in adults and children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 283-300.	1.0	35
75	Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association. Journal of Rheumatology, 2016, 43, 1773-1776.	1.0	23
76	Vascular Imaging Outcomes of Childhood Primary Angiitis of the Central Nervous System. Pediatric Neurology, 2016, 63, 53-59.	1.0	20
77	Inter-Rater Reliability of the CASCADE Criteria. Stroke, 2016, 47, 2443-2449.	1.0	30
78	Comment on: real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome: reply. Rheumatology, 2016, 55, 1340.1-1341.	0.9	0
79	Central Nervous System Vasculitis. , 2016, , 500-506.e2.		0
80	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
81	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
82	Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology, 2016, 55, 689-696.	0.9	55
83	<i>GRIN1</i> polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e153.	3.1	5
84	Treatment of CNS Vasculitis in Children. Current Treatment Options in Rheumatology, 2015, 1, 365-380.	0.6	3
85	Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. Pediatric Rheumatology, 2015, 13, 43.	0.9	42
86	<i>HLA-DRB1*11</i> ionim are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
87	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
88	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.5	239
89	Dynamic knee joint function in children with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2015, 13, 8.	0.9	16
90	The growing spectrum of antibody-associated inflammatory brain diseases in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e92.	3.1	30

#	Article	IF	Citations
91	Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatric Nephrology, 2015, 30, 113-121.	0.9	18
92	Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire. Open Rheumatology Journal, 2015, 9, 16-20.	0.1	7
93	What Matters Most for Patients, Parents, and Clinicians in the Course of Juvenile Idiopathic Arthritis? A Qualitative Study. Journal of Rheumatology, 2014, 41, 2260-2269.	1.0	32
94	A157: Macrophage Activation Syndrome-like Illness Due to an Activating Mutation in NLRC4. Arthritis and Rheumatology, 2014, 66, S203-S203.	2.9	4
95	A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience. Arthritis and Rheumatology, 2014, 66, S220-S221.	2.9	7
96	Challenges in Diagnosing Muckleâ€Wells Syndrome: Identifying Two Distinct Phenotypes. Arthritis Care and Research, 2014, 66, 765-772.	1.5	17
97	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69
98	Distinct Phenotype Clusters in Childhood Inflammatory Brain Diseases: Implications for Diagnostic Evaluation. Arthritis and Rheumatology, 2014, 66, 750-756.	2.9	26
99	The rapidly expanding world of rapidly progressive encephalopathy. Annals of Neurology, 2014, 75, 334-336.	2.8	2
100	A15: Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis. Arthritis and Rheumatology, 2014, 66, S25-S25.	2.9	3
101	Childhood inflammatory brain diseases: pathogenesis, diagnosis and therapy. Rheumatology, 2014, 53, 1359-1368.	0.9	39
102	A96: The Roller Coaster of Juvenile Idiopathic Arthritis: A Qualitative Examination of Parents' Emotional Responses to the Disease and Its Management. Arthritis and Rheumatology, 2014, 66, S131-S131.	2.9	2
103	Anti–Glutamic Acid Decarboxylase Antibody Associated Limbic Encephalitis in a Child. Journal of Child Neurology, 2014, 29, 677-683.	0.7	34
104	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.5	275
105	An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nature Genetics, 2014, 46, 1140-1146.	9.4	585
106	Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?. Nature Reviews Rheumatology, 2014, 10, 682-690.	3.5	17
107	The New Histopathologic Classification of ANCA-Associated GN and Its Association with Renal Outcomes in Childhood. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1684-1691.	2.2	48
108	IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 115-123.	0.9	212

#	Article	IF	Citations
109	Systemic inflammatory and autoimmune disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1243-1252.	1.0	27
110	Fibromuscular dysplasia and childhood stroke. Brain, 2013, 136, 1846-1856.	3.7	73
111	Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Research and Therapy, 2013, 15, R64.	1.6	63
112	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurology, The, 2013, 12, 157-165.	4.9	2,382
113	CNS vasculitis in children. Multiple Sclerosis and Related Disorders, 2013, 2, 162-171.	0.9	24
114	Childhood Central Nervous System Vasculitis. Neuroimaging Clinics of North America, 2013, 23, 293-308.	0.5	28
115	Anti–NMDA Receptor Encephalitis. Neuroimaging Clinics of North America, 2013, 23, 309-320.	0.5	39
116	Childhood central nervous system vasculitis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1065-1078.	1.0	21
117	Hearing loss in Muckleâ€Wells syndrome. Arthritis and Rheumatism, 2013, 65, 824-831.	6.7	59
118	Psychiatric Illness of Systemic Lupus Erythematosus in Childhood: Spectrum of Clinically Important Manifestations. Journal of Rheumatology, 2013, 40, 506-512.	1.0	38
119	Longterm Outcomes and Damage Accrual in Patients with Childhood Systemic Lupus Erythematosus with Psychosis and Severe Cognitive Dysfunction. Journal of Rheumatology, 2013, 40, 513-519.	1.0	31
120	Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Annals of the Rheumatic Diseases, 2013, 72, 1628-1633.	0.5	123
121	Refractory Primary Central Nervous System Vasculitis of Childhood: Successful Treatment with Infliximab. Journal of Rheumatology, 2012, 39, 2227-2229.	1.0	22
122	von Willebrand factor antigena possible biomarker of disease activity in childhood central nervous system vasculitis?. Rheumatology, 2012, 51, 1838-1845.	0.9	35
123	Jointly managing arthritis. Journal of Child Health Care, 2012, 16, 124-140.	0.7	24
124	Towards a Consensus-Based Classification of Childhood Arterial Ischemic Stroke. Stroke, 2012, 43, 371-377.	1.0	144
125	Increased Sensitivity of the European Medicines Agency Algorithm for Classification of Childhood Granulomatosis with Polyangiitis. Journal of Rheumatology, 2012, 39, 1687-1697.	1.0	35
126	Primary and Secondary Central Nervous System Vasculitis. Journal of Child Neurology, 2012, 27, 1448-1459.	0.7	37

#	Article	IF	Citations
127	The spectrum of CNS vasculitis in children and adults. Nature Reviews Rheumatology, 2012, 8, 97-107.	3.5	63
128	Childhood primary angiitis of the central nervous system: Identifying disease trajectories and early risk factors for persistently higher disease activity. Arthritis and Rheumatism, 2012, 64, 1665-1672.	6.7	45
129	Granulomatosis with Polyangiitis in Childhood. Current Rheumatology Reports, 2012, 14, 107-115.	2.1	25
130	Distinguishing features in the presentations of childhood inflammatory brain diseases at a tertiary-care centre. Pediatric Rheumatology, 2012, 10, .	0.9	1
131	Primary angiitis of the CNS. Lancet Neurology, The, 2011, 10, 561-572.	4.9	303
132	NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Research and Therapy, 2011, 13, R196.	1.6	51
133	Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis and Rheumatism, 2011, 63, 840-849.	6.7	147
134	Anti– <i>N</i> â€methylâ€ <scp>D</scp> â€aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. Arthritis and Rheumatism, 2011, 63, 2516-2522.	6.7	70
135	MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases, 2011, 70, 2075-2081.	0.5	57
136	Posterior Reversible Encephalopathy Syndrome: Increasing Recognition of an Important Clinical Entity in Young Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2011, 38, 1544-1545.	1.0	4
137	Diagnosing central nervous system vasculitis in children. Current Opinion in Pediatrics, 2010, 22, 731-738.	1.0	29
138	Central nervous system vasculitis in children. Current Opinion in Rheumatology, 2010, 22, 590-597.	2.0	64
139	Takayasu arteritis in children and adolescents. Rheumatology, 2010, 49, 1806-1814.	0.9	182
140	Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study. Lancet Neurology, The, 2010, 9, 1078-1084.	4.9	132
141	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
142	<i>Pneumocystis jiroveci</i> pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care and Research, 2010, 62, 1661-1664.	1.5	54
143	Brain biopsy in children with primary smallâ€vessel central nervous system vasculitis. Annals of Neurology, 2010, 68, 602-610.	2.8	109
144	Risk factors for severe Muckleâ€Wells syndrome. Arthritis and Rheumatism, 2010, 62, 3783-3791.	6.7	46

#	Article	IF	Citations
145	Severe Ulcerative Colitis After Rituximab Therapy. Pediatrics, 2010, 126, e243-e246.	1.0	144
146	Autoantibodies in Pediatric Systemic Lupus Erythematosus: Ethnic Grouping, Cluster Analysis, and Clinical Correlations. Journal of Rheumatology, 2009, 36, 416-421.	1.0	64
147	Ethnic Differences in Pediatric Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 2539-2546.	1.0	136
148	Comparison of Factors Associated With Coronary Artery Dilation Only Versus Coronary Artery Aneurysms in Patients With Kawasaki Disease. American Journal of Cardiology, 2009, 104, 1743-1747.	0.7	58
149	Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study. Arthritis and Rheumatism, 2009, 61, 1077-1086.	6.7	68
150	B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus. Pediatrics, 2009, 123, e159-e163.	1.0	61
151	Rolandic Mitochondrial Encephalomyelopathy and MT-ND3 Mutations. Pediatric Neurology, 2009, 41, 27-33.	1.0	31
152	Experience With Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome at a Single Institution. Journal of Pediatric Hematology/Oncology, 2009, 31, 81-84.	0.3	52
153	The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2008, 51, 402-404.	0.8	105
154	A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 206-213.	6.7	100
155	Clinical and Laboratory Characteristics and Long-Term Outcome of Pediatric Systemic Lupus Erythematosus: A Longitudinal Study. Journal of Pediatrics, 2008, 152, 550-556.	0.9	286
156	Childhood CNS vasculitis: a treatable cause of new neurological deficit in children. Nature Clinical Practice Rheumatology, 2008, 4, 460-461.	3.2	14
157	Central nervous system vasculitis in children. Current Opinion in Rheumatology, 2008, 20, 47-54.	2.0	107
158	Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2007, 33, 471-498.	0.8	35
159	Central nervous system vasculitis in children. Current Rheumatology Reports, 2006, 8, 442-449.	2.1	36
160	Primary central nervous system vasculitis in children. Arthritis and Rheumatism, 2006, 54, 1291-1297.	6.7	202
161	Angiography-negative primary central nervous system vasculitis in children: A newly recognized inflammatory central nervous system disease. Arthritis and Rheumatism, 2005, 52, 2159-2167.	6.7	144
162	Infections and Kawasaki Disease: Implications for Coronary Artery Outcome. Pediatrics, 2005, 116, e760-e766.	1.0	127

#	Article	IF	CITATIONS
163	Systemic Lupus Erythematosus. Pediatric Clinics of North America, 2005, 52, 443-467.	0.9	90
164	Central nervous system vasculitis in children. Current Opinion in Rheumatology, 2004, 16, 43-50.	2.0	72